Why French trial may have gone horribly wrong

Organisation: Position: Deadline Date: Location:

Scientists are one step closer to understanding how a clinical trial in France killed one volunteer and led to the hospitalisation of five others in January 2016, most likely through ‘off-target’ effects, a Dutch study found.

A study shows that the compound tested in the study, BIA 10-2474, has effects on many other enzymes in addition to the one it was supposed to inhibit. These “off-target” effects might explain why the drug caused side effects ranging from headaches to irreversible brain damage.

“We suspected that BIA 10-2474 was a bad compound – now we know for sure,” says neuro-pharmacologist Daniele Piomelli from the University of California – Irvine, who was not involved in the new study.

The molecule was produced by Portuguese drugmaker Bial and tested in healthy human volunteers in a phase I study by the French contract research company Biotrial in Rennes. BIA 10-2474 inhibits an enzyme called fatty acid amide hydrolase (FAAH), which breaks down endocannabinoids in the brain. Previous research had suggested that FAAH inhibitors might help treat anxiety, chronic pain, or neurodegenerative disorders such as Parkinson’s disease. Although other drug developers, including Pfizer, had already dropped FAAH inhibitors because of disappointing efficacy studies, most of the molecules were shown to be safe, as the US Food and Drug Administration confirmed in August 2016.

But that was not true for BIA 10-2474. Neuroscientist Steven Kushner of Erasmus University Medical Centre in Rotterdam, the Netherlands, together with chemical biologist Mario van der Stelt from nearby Leiden University and colleagues at several other institutes, set out to find out why.

The researchers used a technique called activity-based protein profiling, which allowed them to screen the molecule’s activity against a very large group of enzymes in living human cells. They found that at higher concentrations, the Bial drug disrupted the activity of several lipases, enzymes that break down fatty acids; the Pfizer drug, by contrast, did not. One of the off-target enzymes is called PNPLA6; previous studies have linked defects in the gene encoding for PNPLA6 to rare neurological disorders. The results suggest that BIA 10-2474 may disrupt how neurons in the cerebral cortex metabolize lipids, the team reports.

The researchers can’t be sure that the off-target effects actually caused the brain damage seen in the volunteers, however. “We do not have evidence for a causal relationship yet,” van der Stelt says. One way to find out might be to analyse samples of the deceased volunteer’s brain.

The off-target effects can be species-dependent, says van der Stelt, which could explain why studies in rats and mice did not identify the drug’s danger. But Bial could have known about the risk if it had thoroughly screened for off-target effects in human cells, like the new study does, van der Stelt says; that’s what Pfizer did with its FAAH inhibitor. “If Bial had done the same, they might have reached a different conclusion,” van der Stelt says.

Jürg Gertsch, a biochemist at the University of Bern, agrees; he says it’s “unbelievable” that Bial did not do a more extensive study of the drug’s effects before giving it to humans. Gertsch has himself investigated the effects of BIA 10-2474 in human blood cells; that study has yet to be published.

“The new study does not provide an explanation for the toxicity observed with the compound BIA 10-2474, but does highlight its promiscuous nature,” says Pomelli, who calls the decision to move forward with the human trial “deeply misguided.” He says the doses given to the volunteers in the group where the accident occurred were also unnecessarily high, as full inhibition of FAAH occurred at a much lower level.

Bial welcomes “any study” that could help shed light on the incident, a spokesperson says. They add that results from the company’s own investigation largely align with the new paper, but that in Bial’s opinion, they are unlikely to explain the neurological effects seen in the study.

Although Bial and Biotrial have been heavily criticised for the study, French authorities have concluded that the companies did not violate clinical trial regulations. In the wake of the case, the European Medicines Agency is developing stricter rules for “first-in-human” studies.

Abstract
A recent phase 1 trial of the fatty acid amide hydrolase (FAAH) inhibitor BIA 10-2474 led to the death of one volunteer and produced mild-to-severe neurological symptoms in four others. Although the cause of the clinical neurotoxicity is unknown, it has been postulated, given the clinical safety profile of other tested FAAH inhibitors, that off-target activities of BIA 10-2474 may have played a role. Here we use activity-based proteomic methods to determine the protein interaction landscape of BIA 10-2474 in human cells and tissues. This analysis revealed that the drug inhibits several lipases that are not targeted by PF04457845, a highly selective and clinically tested FAAH inhibitor. BIA 10-2474, but not PF04457845, produced substantial alterations in lipid networks in human cortical neurons, suggesting that promiscuous lipase inhibitors have the potential to cause metabolic dysregulation in the nervous system.

Authors
Annelot CM van Esbroeck, Antonius PA Janssen, Armand B Cognetta III, Daisuke Ogasawara, Guy Shpak, Mark van der Kroeg, Vasudev Kantae, Marc P Baggelaar, Femke MS de Vrij, Hui Deng, Marco Allarà, Filomena Fezza, Zhanmin Lin, Tom van der Wel, Marjolein Soethoudt, Elliot D Mock, Hans den Dulk, Ilse L Baak, Bogdan I Florea, Giel Hendriks, Luciano De Petrocellis, Herman S Overkleeft, Thomas Hankemeier, Chris I De Zeeuw, Vincenzo Di Marzo, Mauro Maccarrone, Benjamin F Cravatt, Steven A Kushner,
Mario van der Stelt

Science Mag material
Science journal abstract


Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.